Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical…

Overview of attention for article published in Health Economics Review, December 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users
facebook: 1 Facebook page

reddit: 1 Redditor

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 69 Mendeley

Summary X Facebook Reddit Dimensions citations

So far, Dimensions has found 13 publications that cite this research output.

13

The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

Article in BMC Infectious Diseases (April 2024)

Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain

Preprint in Research Square (January 2024)

Hypoxia inducible factors inhibit respiratory syncytial virus infection by modulation of nucleolin expression

Article in iScience (December 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.